Jansen vaccine is being studied again in Europe due to suspected thrombosis – Alain ROBERT / SIPA
The European Medicines Agency (EMA) announced that it will give its opinion on the Johnson & Johnson vaccine against Covid-19 on Tuesday, the use of which is suspended in the United States and Europe due to the rare occurrence severe blood clots.
The EMA, which has its headquarters in Amsterdam, underlined Friday in a press release that it would organize on April 20, a priori at 3:00 p.m., a “virtual press conference on the conclusions about the safety assessment” of this single-dose vaccine.
Thrombosis worries
US health authorities on Tuesday recommended “a pause” in the use of Johnson & Johnson to investigate the occurrence of serious cases of blood clots in several people in the United States.
That suspension was extended the next day by at least a week, after a panel of experts said they needed more time to investigate the matter. The American pharmaceutical group Johnson & Johnson, for its part, let it be known on Tuesday that it had “taken the decision to delay the deployment” of its vaccine against Covid-19 in Europe after the recommendation on the “pause” in its use in the States -United.
A person died of blood thrombosis in the United States after receiving this vaccine, an official of the United States Medicines Agency (FDA) announced on Tuesday. Six cases of women who developed severe cases of blood clots in association with low platelet levels after receiving Johnson & Johnson have been reported in the United States.